These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 7703481)

  • 1. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
    Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
    Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
    Sniecinski I; O'Donnell MR; Nowicki B; Hill LR
    Blood; 1988 May; 71(5):1402-7. PubMed ID: 3282572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
    Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
    Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
    Sandler SG
    Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloimmunization to platelets in heavily transfused patients with sickle cell disease.
    Friedman DF; Lukas MB; Jawad A; Larson PJ; Ohene-Frempong K; Manno CS
    Blood; 1996 Oct; 88(8):3216-22. PubMed ID: 8874223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases.
    Pai SC; Lo SC; Lin Tsai SJ; Chang JS; Lin DT; Lin KS; Lin LI
    Transfusion; 2010 Nov; 50(11):2318-27. PubMed ID: 20497513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet alloimmunization after transfusion. A prospective study in 117 heart surgery patients.
    Taaning E; Simonsen AC; Hjelms E; Svejgaard A; Morling N
    Vox Sang; 1997; 72(4):238-41. PubMed ID: 9228715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions.
    Brand A; Claas FH; Voogt PJ; Wasser MN; Eernisse JG
    Vox Sang; 1988; 54(3):160-6. PubMed ID: 3369136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.
    van Marwijk Kooy M; van Prooijen HC; Moes M; Bosma-Stants I; Akkerman JW
    Blood; 1991 Jan; 77(1):201-5. PubMed ID: 1984797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bedside filtration of blood products in the prevention of HLA alloimmunization--a prospective randomized study. Alloimmunisation Study Group.
    Williamson LM; Wimperis JZ; Williamson P; Copplestone JA; Gooi HC; Morgenstern GR; Norfolk DR
    Blood; 1994 May; 83(10):3028-35. PubMed ID: 8180400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-specific antibodies in transfused patients.
    Uhrynowska M; Zupańska B
    Eur J Haematol; 1996 Apr; 56(4):248-51. PubMed ID: 8641394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
    Eernisse JG; Brand A
    Exp Hematol; 1981 Jan; 9(1):77-83. PubMed ID: 7238644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
    Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
    Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
    Trial to Reduce Alloimmunization to Platelets Study Group
    N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia.
    Kekomäki S; Volin L; Koistinen P; Koivunen E; Koskimies S; Ruutu T; Timonen T; Kekomäki R
    Eur J Haematol; 1998 Feb; 60(2):112-8. PubMed ID: 9508352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of platelet refractoriness in oncohematologic patients.
    Ferreira AA; Zulli R; Soares S; Castro Vd; Moraes-Souza H
    Clinics (Sao Paulo); 2011; 66(1):35-40. PubMed ID: 21437433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of platelet alloantibody in multiply-transfused haematology patients.
    Linn YC; Prakash P; Ong YW
    Ann Acad Med Singap; 1995 Mar; 24(2):305-11. PubMed ID: 7653976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.